StockNews.AI
TVTX
StockNews.AI
74 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

1. Pomerantz LLP is investigating claims against Travere Therapeutics for potential securities fraud. 2. The FDA plans an advisory meeting regarding Travere's drug approval application. 3. Travere's stock dropped 20.57% following the FDA disclosure on May 15, 2025.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The investigation signals potential legal troubles and loss of investor confidence, akin to past fraud cases impacting stock prices significantly.

How important is it?

Legal investigations often lead to stock price volatility and decreased investor trust, making this highly relevant for TVTX.

Why Short Term?

Immediate effects on stock due to legal investigations can lead to significant price movements, as seen previously in biotech stocks facing similar challenges.

Related Companies

NVSVRTXAMGN
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Travere and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 15, 2025, Travere issued a press release disclosing that the U.S. Food and Drug Administration (“FDA”) “has indicated that it is currently planning to hold an advisory committee meeting to discuss” the Company’s “supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS).”  On this news, Travere’s stock price fell $4.35 per share, or 20.57%, to close at $16.80 per share on May 16, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.  CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News